Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR-Reduced (Empagliflozin Outcome Trials in Chronic Heart Failure With Reduced Ejection Fraction) and EMPEROR-Preserved (Empagliflozin O...

Descripción completa

Detalles Bibliográficos
Autores principales: Packer, Milton, Butler, Javed, Zeller, Cordula, Pocock, Stuart J., Brueckmann, Martina, Ferreira, João Pedro, Filippatos, Gerasimos, Usman, Muhammad Shariq, Zannad, Faiez, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516173/
https://www.ncbi.nlm.nih.gov/pubmed/37621153
http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516173/
https://www.ncbi.nlm.nih.gov/pubmed/37621153
http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065748

Ejemplares similares